IFNA1 and hepatitis C virus infection: High CXCL10 levels have been associated with weaker responses to therapy in hepatitis C virus infection [20], [21], while, in contrast, higher CXCL10 levels correlated with more pronounced declines of HBsAg during polymerase inhibitor therapies in hepatitis B [22] and also PEG-IFNα-based HBV treatment [23].